Joint with: Drug Delivery to the Brain: Emerging Modalities
Antibodies as Drugs: Innovative Formats, Design and Engineering
February 17-20, 2025 | Keystone Resort, Keystone, CO, United States
Scientific Organizers:
Jean-Philippe Julien and Katherine Harris
In Person
On Demand
February 17-20, 2025 | Keystone Resort, Keystone, CO, United States
Scientific Organizers:
Jean-Philippe Julien and Katherine Harris
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Booking Function
Monday, February 17, 2025
Fundraising
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Tuesday, February 18, 2025
Breakfast
7:00–8:00 AM
Welcome and Keynote Address
8:00–9:00 AM
Bahija Jallal, Immunocore LLC
Talk Title to be Announced
Talk Title to be Announced
Antibody-Based Protein Degraders for Therapeutics Development
9:00–11:15 AM
James A. Wells, University of California, San Francisco
AbTACs
AbTACs
Steve Staben †, Lycia Therapeutics
Talk Title to be Announced
Talk Title to be Announced
Leo James, MRC Laboratory of Molecular Biology
Talk Title to be Announced
Talk Title to be Announced
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
On Own for Lunch
11:15–5:00 PM
Poster Setup
11:15–1:00 PM
Poster Viewing
1:00–10:00 PM
Workshop 1: Preclinical Development of Antibody Therapeutics: From Discovery to IND
1:30–3:15 PM
Short Talk(s) Chosen from Abstracts
Career Roundtable (Joint)
3:30–4:30 PM
Coffee Available
4:30–5:00 PM
New Developments in Antibody Drug Conjugate Technology
5:00–7:00 PM
Alain Beck, Pierre Fabre
Current and Next Generation ADCs Successes and Failures
Current and Next Generation ADCs Successes and Failures
Patricia LoRusso, Yale School of Medicine
ADCs: Selection, Resistance and Combinations
ADCs: Selection, Resistance and Combinations
Seema Kantak, Exelixis
Discovery of XB010, a Next Generation 5T4-targeting ADC
Discovery of XB010, a Next Generation 5T4-targeting ADC
Scott A. Lesley, InduPro
Proximity-based Bispecific Antibody Strategies to Address Disease
Proximity-based Bispecific Antibody Strategies to Address Disease
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Wednesday, February 19, 2025
Breakfast
7:00–8:00 AM
Pushing the Boundaries of Biologics Towards Precision
8:00–11:00 AM
Benjamí Oller-Salvia, Ramon Llull University
Novel Approaches for Conditionally-Active and Brain-Permeable Antibodies
Novel Approaches for Conditionally-Active and Brain-Permeable Antibodies
Mark S. Cragg, University of Southampton
Developing Immunostimulating Antibodies to Deliver Agonism Without Toxicity
Developing Immunostimulating Antibodies to Deliver Agonism Without Toxicity
Leah Sibener, 3T Biosciences
TCR Biologics
TCR Biologics
David G. Kugler, Cartography Biosciences
Identifying Optimal Targets and Target Pairs for Multi-Specific Targeted Therapies
Identifying Optimal Targets and Target Pairs for Multi-Specific Targeted Therapies
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Poster Setup
11:00–1:00 PM
Poster Viewing
1:00–10:00 PM
Coffee Available
4:30–5:00 PM
Technologies to Increase Drug Accessibility against Infectious Diseases on a Global Scale
5:00–7:00 PM
Nico Callewaert, VIB and Ghent University
VHH-Fc for Engineered Yeast Manufacturing
VHH-Fc for Engineered Yeast Manufacturing
Anja F. Hohmann, Be Biopharma
B Cell Medicines Designed for Sustained Delivery of Therapeutic Biologics
B Cell Medicines Designed for Sustained Delivery of Therapeutic Biologics
Christopher O. Barnes, Stanford University
Antibody Therapeutics Against Respiratory RNA Viruses
Antibody Therapeutics Against Respiratory RNA Viruses
Jean-Philippe Julien, Hospital for Sick Children Research Institute
Mutabody Technology to Enhance Potency and Breadth of Antibodies for Global Health
Mutabody Technology to Enhance Potency and Breadth of Antibodies for Global Health
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Thursday, February 20, 2025
Breakfast
7:00–8:00 AM
Therapeutic Applications of Fc Domain Engineering
8:00–11:00 AM
Taia Wang, Stanford University
IgG Fc Glycan Composition in Human Immunity
IgG Fc Glycan Composition in Human Immunity
E. Sally Ward, University of Southampton
Targeting FcRn for the Generation of Therapeutics for Antibody-Mediated Disease
Targeting FcRn for the Generation of Therapeutics for Antibody-Mediated Disease
John R. Desjarlais, Xencor, Inc.
Optimization and Application of Fc-Containing Bispecific Antibodies
Optimization and Application of Fc-Containing Bispecific Antibodies
Karen Silence, ArGEN-X
Engineering of Antibodies for Optimal FcRn Engagement
Engineering of Antibodies for Optimal FcRn Engagement
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Workshop 2: Leveraging AI and ML in Antibody Discovery, Engineering and Beyond
2:30–4:30 PM
Short Talk(s) Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Novel Antibody Therapies and Combinations
5:00–6:45 PM
Rony Dahan, Weizmann Institute of Science
Bispecific Immune Synapse Engagers for Cancer Immunotherapy
Bispecific Immune Synapse Engagers for Cancer Immunotherapy
Katherine Harris, Rondo Therapeutics
Bispecific Antibody Combination Strategies for Treating Solid Tumors
Bispecific Antibody Combination Strategies for Treating Solid Tumors
Katherine Cygnar, Regeneron Pharmaceuticals
Optimizing BBB-Crossing Antibodies and Antibody-Targeted Cargo
Optimizing BBB-Crossing Antibodies and Antibody-Targeted Cargo
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Social Hour with Lite Bites
7:00–8:00 PM
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Friday, February 21, 2025
Departure
12:00–11:59 PM
Subscribe for Updates